Abstract
Stress exposure represents a major environmental risk factor for schizophrenia and other psychiatric disorders, as it plays a pivotal role in the etiology as well as in the manifestation of disease symptomatology. It may be inferred that pharmacological treatments must be able to modulate the behavioral, functional, and molecular alterations produced by stress exposure to achieve significant clinical outcomes. This review aims at examining existing clinical and preclinical evidence that supports the ability of atypical antipsychotic drugs (AAPDs) to modulate stress-related alterations. Indeed, while the pharmacodynamic differences between AAPDs have been extensively characterized, less is known on their ability to regulate downstream mechanisms that are critical for functional recovery and patient stabilization. We will discuss stress-related mechanisms, spanning from neuroendocrine function to inflammation and neuronal plasticity, which are relevant for the manifestation of schizophrenic symptomatology, and we will discuss if and how AAPDs may interfere with such mechanisms. Considering the impact of stress in everyday life, we believe that a better understanding of the potential effects of AAPDs on stress-related mechanisms may provide novel and important insights for improving therapeutic strategies aimed at promoting coping mechanisms and enhancing the quality of life of patients affected by psychiatric disorders.
Highlights
Stress and Mental IllnessThe term “stress” indicates an experience that may be perceived as challenging, both emotionally and physiologically, which implies a whole-body reaction to such a challenging event [1,2]
This review aims at examining existing clinical and preclinical evidence that supports the ability of atypical antipsychotic drugs (AAPDs) to modulate stress-related alterations
Considering the impact of stress in everyday life, we believe that a better understanding of the potential effects of AAPDs on stress-related mechanisms may provide novel and important insights for improving therapeutic strategies aimed at promoting coping mechanisms and enhancing the quality of life of patients affected by psychiatric disorders
Summary
The term “stress” indicates an experience that may be perceived as challenging, both emotionally and physiologically, which implies a whole-body reaction to such a challenging event [1,2]. Several aspects concur in the response to stress, such as genetic makeup, previous life experiences, and the timing of stress exposure, which modulate the ability of the subject to adapt and respond to the challenging situation. It is important to establish if and to what extent pharmacological intervention may be able to counteract stress-induced alterations and promote coping mechanisms to reduce the negative effects of stress exposure. On these premises, this review will discuss selected stress-related mechanisms that may be relevant for the manifestation of schizophrenic symptoms, to evaluate the ability of atypical antipsychotic drugs (AAPDs) to modulate or interfere with such mechanisms. To provide a deeper knowledge of certain aspects, we included “milestone” papers of the field
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
